JILLIAN STEVENS: Open Payments
NPI 1992358725 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,523 in 58 payments from 18 companies in 2025. Trend: 2023 $740 · 2024 $1,740 · 2025 $1,523
Food & beverage: $1,514Education: $10
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $392 |
| Incyte Corporation | 6 | $167 |
| ABBVIE INC. | 10 | $165 |
| UCB, Inc. | 4 | $132 |
| Arcutis Biotherapeutics, Inc. | 4 | $117 |
| Regeneron Healthcare Solutions, Inc. | 3 | $109 |
| LEO Pharma Inc. | 4 | $90 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 3 | $71 |
| Galderma Laboratories, L.P. | 4 | $62 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 2 | $43 |
Products named: DUPIXENT, OPZELURA, Bimzelx, Zoryve, ADBRY, SKYRIZI, NEMLUVIO, ILUMYA.
Industry payments across CA — which companies pay providers there.
